Non-Small Cell Lung Cancer Recurrent and Metastatic Disease

On this page

Quick Reference

RxDrug of choiceOsimertinib 80 mg daily for EGFR-mutant NSCLC; pembrolizumab 200 mg IV every 3 weeks for PD-L1 ≥50% without driver alterations

AltAlternativesAumolertinib 110 mg daily + platinum-pemetrexed for EGFR-mutant; sunvozertinib 300 mg daily for EGFR exon20ins; poziotinib 16 mg daily for HER2 exon20ins; lazertinib 240 mg daily + SBRT for oligometastatic EGFR-mutant

⊘AvoidNon-dihydropyridine CCBs (diltiazem, verapamil) in EGFR-mutant patients, avoid; bevacizumab added to osimertinib for T790M+ progression (no benefit, increased toxicity); concurrent chemotherapy with reirradiation (adds toxicity without clear benefit); SBRT for ultra-central tumors outside clinical trials

DxTest of choicePET/CT for initial detection of suspected recurrence; tissue biopsy with repeat molecular profiling (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, PD-L1); tumor-informed ctDNA MRD testing for early relapse detection

ScKey scoreALBI grade (albumin-bilirubin), grade 1 best prognosis on anti-PD-1 therapy; grade 2 HR 1.60, grade 3 for OS

→When to referRadiation oncology for SBRT or reirradiation; neurosurgery for brain metastases; palliative care for symptom management; clinical trial for patients with progression on standard therapy

Recurrent NSCLC requires repeat molecular profiling to guide therapy; isolated locoregional recurrence may be curable with salvage surgery or reirradiation; distant disease is managed with biomarker-directed systemic therapy (osimertinib ± chemo or ramucirumab, sunvozertinib, poziotinib, pembrolizumab); oligometastatic disease (≤5 lesions) benefits from SBRT added to targeted therapy or immunotherapy; CNS-penetrant agents and double-dose osimertinib are key for brain metastases.

This guide summarizes the management of recurrent and metastatic non-small cell lung cancer (NSCLC), covering patterns of recurrence, diagnostic workup, local-regional salvage options, systemic therapy for distant disease, oligometastatic treatment, and prognostic factors. It emphasizes actionable clinical data, including drug doses, key thresholds, and evidence-based pearls.

Overview and Recommendations

Background

•Recurrent NSCLC after initial curative-intent therapy (surgery, radiation, or chemoradiation) is classified by disease extent: local (same lobe), regional (ipsilateral hilum, mediastinum, or supraclavicular nodes), or distant (contralateral lung, pleura, liver, brain, bone). The pattern determines the salvage approach, isolated locoregional recurrence may be amenable to aggressive local therapy, while distant relapse almost always requires systemic treatment.
•The risk of recurrence is driven by tumor biology: intratumor copy-number heterogeneity (HR 4.9), visceral pleural invasion (5-year DFS 53.3% vs 65.9% without), and non-inflamed immune phenotype (KEAP1/STK11 co-mutations). ALK-positive NSCLC carries a high risk of brain relapse; adjuvant ensartinib 225 mg daily for 24 months reduced 24-month disease recurrence from 46.5% to 13.6% (HR 0.20).
•Molecular drivers evolve under selective pressure from prior therapy. Repeat biopsy (tissue or plasma ctDNA) is essential to identify resistance mechanisms (e.g., EGFR T790M after first-generation TKIs, bypass-track activation, or histologic transformation) and to detect new actionable alterations (EGFR, ALK, ROS1, BRAF V600E, METex14, RET, NTRK, KRAS G12C). PD-L1 expression may also change.
•Oligometastatic disease, defined as ≤5 lesions in ≤3 organs (NCCN) or ≤3 lesions (ESMO), represents a prognostically favorable subset. Metastasis-directed therapy with SBRT or resection can delay systemic therapy escalation and improve outcomes. The ABLATE trial in EGFR-mutant NSCLC showed that adding SBRT to lazertinib 240 mg daily extended median PFS to 34.0 months vs 24.8 months with lazertinib alone.
•Approximately 50% of patients with stage III NSCLC treated with chemoradiotherapy plus durvalumab will recur; of those, 72% have oligorecurrence (≤3 lesions). The most common sites are lung (34%) and brain (26%), and salvage local therapy significantly improves survival after recurrence (OS2).

Evaluation

•Suspect recurrence in any patient with treated NSCLC who develops new respiratory symptoms (cough, dyspnea, hemoptysis), constitutional symptoms (weight loss, fatigue), or neurologic deficits (headache, seizure, focal weakness). Routine surveillance imaging (CT chest with contrast) is performed every 3-6 months for the first 2-3 years, then annually.
•If CT findings are equivocal, or if there is clinical suspicion despite negative CT, order [18F]FDG PET/CT. PET/CT has significantly higher sensitivity (88% vs 62% for CT) for detecting recurrence, especially after chemoradiotherapy (100% vs 46%) and within the first 6 months after treatment (83% vs 41%). Specificity is lower (89% vs 96%) due to post-radiation inflammation.
•When imaging suggests recurrence, obtain histologic confirmation via image-guided core needle biopsy (CT or ultrasound) or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal/hilar lesions. A negative biopsy in a high-suspicion lesion should prompt repeat biopsy or multidisciplinary discussion.
•Perform repeat molecular profiling on the rebiopsy specimen: test for EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, KRAS G12C, and PD-L1 (22C3 or comparable assay). Resistance mutations (e.g., EGFR T790M) guide subsequent TKI selection. If tissue is insufficient, consider plasma ctDNA testing.
•Assess circulating tumor DNA (ctDNA) for molecular residual disease (MRD) and early relapse detection. Tumor-informed ctDNA assays (e.g., PROPHET) have a median lead time of 299 days to radiologic recurrence. In the LUNGCA-1 cohort, ctDNA positivity at postoperative day 3 or month 1 predicted relapse (HR 11.1), and MRD-positive patients who received adjuvant therapy had improved RFS (HR 0.3).
•Calculate the albumin-bilirubin (ALBI) grade as a simple prognostic tool. ALBI grade 2 vs 1 is associated with HR 1.60 for OS on anti-PD-1 therapy; grade 3 vs 1 with. This readily available lab value stratifies survival even in patients with ECOG PS 1-3 and can inform treatment decisions.
•For patients with isolated brain recurrence, obtain dedicated brain MRI with contrast. If leptomeningeal metastases are suspected, perform lumbar puncture for CSF cytology and ctDNA analysis.
•Evaluate performance status (ECOG PS), time to recurrence (postoperative recurrence has better prognosis than de novo stage IIIB/IV), and prior treatment history (platinum-free interval, prior TKI use, prior immunotherapy). These factors determine the intensity and choice of salvage therapy.

Management

•For isolated local recurrence after SABR or surgery, consider salvage surgery if R0 resection is feasible. Salvage pneumonectomy after high-dose CRT (≥60 Gy) yields median DFS of 14 months; 90-day mortality is 0% for pneumonectomy and 24% for lobectomy. Favorable outcomes are associated with recurrence >12 months after CRT and R0 resection.
•For local-regional recurrence not amenable to surgery, offer reirradiation with SBRT (preferred) or proton therapy. SBRT to a BED₁₀ ≥100 Gy achieves 2-year local failure of ~21.6% and median OS. Adhere to composite dose constraints: esophagus Dmax <120 Gy, lung V20 <40%, heart V40 <50%, spinal cord Dmax <57 Gy. Avoid concurrent chemotherapy with reirradiation if possible.
•For patients with EGFR-mutant metastatic recurrence and no prior third-generation TKI, start osimertinib 80 mg daily. Consider adding platinum-pemetrexed (4-6 cycles) if CNS metastases are present (FLAURA2: HR 0.58 for CNS progression). Alternatively, add ramucirumab 10 mg/kg IV every 3 weeks (RAMOSE: PFS 24.8 vs 15.6 months; NNT ≈7 at 12 months).
•For EGFR exon 20 insertion mutations in platinum-pretreated patients, use sunvozertinib 300 mg once daily (cORR 47.2%, median DOR 13.8 months). Monitor for grade ≥3 diarrhea (18%). For HER2 exon 20 insertions, poziotinib 16 mg once daily is an option (ORR 27.8%, median PFS 5.5 months) but carries high rates of rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%) requiring dose reductions.
•For CNS-dominant recurrence in EGFR-mutant disease, escalate osimertinib to 160 mg daily (double dose). This achieves intracranial disease control rate of 92.5% and complete response rate of 12.5% in leptomeningeal metastases, with median OS 13.3 months. Alternatively, consider proton craniospinal irradiation (pCSI) which improved CNS PFS (7.5 vs 2.3 months) and OS (9.9 vs 6.0 months) compared to photon involved-field RT.
•For PD-L1-positive (≥1%) NSCLC with untreated brain metastases (5-20 mm, asymptomatic, no corticosteroids), treat with pembrolizumab 10 mg/kg every 2 weeks (brain metastasis response rate 29.7%). No responses are seen in PD-L1-negative patients.
•For oligometastatic disease (≤5 lesions) in treatment-naïve EGFR-mutant NSCLC, add SBRT to all metastatic sites (20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions) to lazertinib 240 mg once daily. The ABLATE trial showed median PFS of 34.0 months with no grade ≥3 radiation pneumonitis.
•For oligometastatic NSCLC without driver mutations, consider SBRT to all sites before or concurrent with immunotherapy. The PEMBRO-RT trial showed that SBRT (3 × 8 Gy) to a single tumor site before pembrolizumab improved ORR from 18% to 36%, especially in PD-L1-negative patients. The SKYROCKET trial reported median PFS of 9.3 months with SBRT + atezolizumab + tiragolumab.
•Do not use non-CNS penetrant first-generation EGFR TKIs (gefitinib, erlotinib) for patients with brain metastases if osimertinib is available. Avoid adding bevacizumab to osimertinib for T790M-positive patients after progression on first/second-generation TKIs (WJOG8715L showed no PFS benefit and increased toxicity). Avoid SBRT for ultra-central tumors outside clinical trials due to ~15% risk of grade 5 hemoptysis.
•Refer all patients with recurrent or metastatic NSCLC to a multidisciplinary tumor board for discussion of salvage local therapy, clinical trial enrollment, and palliative care integration. For patients with brain metastases, involve neurosurgery for consideration of surgical resection or stereotactic radiosurgery, and radiation oncology for whole-brain RT or pCSI if indicated.
•Monitor patients every 3 months with CT chest/abdomen/pelvis and brain MRI if CNS disease is present. Reassess molecular profile at progression. For patients on immunotherapy, monitor for immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies). Discontinue therapy if unacceptable toxicity or confirmed radiographic progression.

Board Review — High Yield

•Pattern of recurrence determiner, Isolated locoregional recurrence after SABR can be salvaged with surgery or reirradiation and yields 5-year OS similar to patients without recurrence (57.9% vs 54.9%). Distant recurrence requires systemic therapy.
•PET/CT superior to CT, Sensitivity 88% vs 62% for detecting recurrence, especially after chemoradiotherapy (100% vs 46%) and within 6 months (83% vs 41%). False positives from inflammation.
•ctDNA MRD, Tumor-informed ctDNA predicts relapse a median of 299 days before imaging; MRD-positive patients benefit from adjuvant therapy (HR 0.3).
•ALBI grade, Simple liver function index (albumin-bilirubin) that independently predicts OS on anti-PD-1 therapy: grade 2 HR 1.60, grade 3.
•FLAURA2, Adding platinum-pemetrexed to osimertinib reduces CNS progression in EGFR-mutant NSCLC (HR 0.58 for CNS progression; 24-month cumulative incidence 9% vs 23%).
•Ramose trial, Adding ramucirumab to osimertinib prolongs PFS (24.8 vs 15.6 months; HR 0.55); NNT ≈7 at 12 months.
•Sunvozertinib for EGFR exon20ins, 300 mg daily yields cORR 47.2%; effective in brain metastases (52.4% ORR in patients with baseline CNS lesions).
•Double-dose osimertinib (160 mg) for leptomeningeal metastases, Intracranial disease control rate 92.5%, median OS 13.3 months.
•ABLATE trial, SBRT to all sites (≤5 lesions) + lazertinib 240 mg daily in EGFR-mutant oligometastatic NSCLC: median PFS 34.0 vs 24.8 months; no grade ≥3 radiation pneumonitis.
•Ultra-central tumors contraindication, SBRT for ultra-central NSCLC carries ~15% risk of grade 5 hemoptysis; reserve for clinical trials.

Deep Dive — Evidence Details

Local-Regional Recurrence

▸Locoregional recurrence after SABR is low (2-year ~5%)
▸Salvage surgery or reirradiation can achieve long-term survival

HY High Yield: For SBRT reirradiation, aim for BED₁₀ ≥100 Gy and adhere to composite dose constraints

Isolated locoregional recurrence after definitive therapy may be curable with salvage surgery or reirradiation. After , 2-year local and regional recurrence rates are 4.9% and 7.8% ^[24]^B3b. After CRT plus , 72% of recurrences are oligorecurrence (≤3 lesions), often in lung (34%) or brain (26%) ^[41]^B2b. Salvage surgery after CRT or immunotherapy is feasible: R0 resection, no perioperative mortality, pCR in 18.8% ^[44]^C4^[49]^B3b. For ALK+ NSCLC on alectinib, salvage surgery yields 90% major pathological response and 50% pCR, but perivascular fibrosis is common (70%) ^[47]^C4. Reirradiation with achieves 2-year local failure ~21.6% and median OS 20.8 months ^[40]^A1c; BED₁₀ ≥100 Gy improves outcomes ^[40]^A1c. may reduce toxicity, but grade ≥3 toxicity occurs in 42% ^[55]^C4.

Organ at risk	Constraint (EQD₂)
Esophagus	V60 <40%, Dmax <100 Gy, avoid >110 Gy, strongly discourage >120 Gy
Lung	V20 <40%, V5 ≤65%, discourage V5 >75%
Heart	V40 <50%, mean heart dose as low as reasonably achievable
Aorta/great vessels	Dmax <120 Gy
Trachea/proximal bronchial tree	Dmax <110 Gy
Spinal cord	Dmax <57 Gy
Brachial plexus	Dmax <85 Gy

Pearl: Isolated locoregional recurrence after definitive therapy for NSCLC is potentially curable; salvage surgery or reirradiation with SBRT or proton therapy can achieve long-term survival in carefully selected patients, and multidisciplinary evaluation, including assessment of R0 resectability, BED ≥100 Gy for SBRT, and adherence to composite dose constraints, is essential.

Distant Metastatic Disease

▸Osimertinib plus chemo or ramucirumab improves PFS in EGFR-mutant NSCLC
▸Double-dose osimertinib or proton CSI for CNS-dominant recurrence

Rx Drug of Choice: Osimertinib 80 mg daily: first-line for EGFR-mutant metastatic NSCLC

Treatment depends on molecular drivers, platinum-free interval, and resistance mechanism. For EGFR-mutant NSCLC, osimertinib 80 mg daily is backbone. Adding platinum-pemetrexed (FLAURA2) improves PFS, especially with CNS metastases (HR 0.58) ^[6]^A1b. Ramucirumab 10 mg/kg IV q3w plus osimertinib (RAMOSE) prolongs PFS to 24.8 vs 15.6 months (HR 0.55) ^[64]^B2b. Aumolertinib 110 mg daily plus chemo (AENEAS2) yields PFS 28.9 vs 18.9 months (HR 0.47) ^[65]^A1b. For T790M after first-generation TKI, osimertinib is standard; adding bevacizumab does not improve PFS ^[71]^B2b. For EGFR exon 20 insertion, sunvozertinib 300 mg daily achieves cORR 47.2% ^[63]^B2b. For HER2 exon 20 insertion, poziotinib 16 mg daily yields ORR 27.8% ^[75]^B2b. For CNS metastases, double-dose osimertinib (160 mg) for leptomeningeal disease gives intracranial DCR 92.5% ^[74]^B2b; proton craniospinal irradiation improves CNS PFS vs photon RT ^[62]^B2b. Pembrolizumab in PD-L1+ brain metastases yields response 29.7% ^[67]^B2b.

Pearl: For patients with EGFR-mutant NSCLC and distant metastatic recurrence, the decision to intensify therapy with chemotherapy or ramucirumab should be guided by the burden of CNS metastases, the platinum-free interval, and the patient's tolerance for added toxicity, the FLAURA2 and RAMOSE regimens both offer clinically meaningful PFS gains but with distinct adverse effect profiles.

Selected First-Line Intensification Regimens for EGFR-Mutant Distant Metastatic NSCLC

Regimen	PFS (months)	HR (95% CI)	CNS benefit	Key toxicity
Osimertinib + platinum-pemetrexed (FLAURA2)	30.2 vs 27.6 (cFAS)	0.58 (0.33-1.01)	42% risk reduction; 59% CNS CR	64% grade ≥3 (cytopenias) ^[6]^A1b
Aumolertinib + platinum-pemetrexed (AENEAS2)	28.9 vs 18.9	0.47 (0.37-0.60)	NR	Neutropenia 55% grade ≥3 ^[65]^A1b
Osimertinib 160 mg (BM/LM cohort)	7.6 (BM), 8.0 (LM)	N/A	CNS ORR 55% (BM), DCR 92.5% (LM)	Grade 1-2 diarrhea, rash ^[74]^B2b

Oligometastatic Disease

▸SBRT + TKI in EGFR-mutant oligometastatic NSCLC improves PFS
▸SBRT safe for most sites except ultra-central tumors

HY High Yield: ABLATE: lazertinib + SBRT PFS 34 months in ≤5 lesions

For ≤5 metastatic lesions (NCCN/IASLC), metastasis-directed therapy with or surgery can prolong disease control. The ABLATE phase II trial in treatment-naïve EGFR-mutant NSCLC (≤5 lesions) showed lazertinib 240 mg daily plus SBRT to all sites yields median PFS 34.0 months vs 24.8 months with lazertinib alone ^[81]^B2b. No grade ≥3 radiation pneumonitis ^[81]^B2b. SBRT plus immunotherapy: PEMBRO-RT (pembrolizumab after SBRT 3×8 Gy) improved ORR from 18% to 36% ^[83]^B2b; SKYROCKET (atezolizumab + tiragolumab after SBRT) reported median PFS 9.3 months ^[86]^B2b. For bone oligometastases, SBRT gives 2-year local control 87.2% with low fracture rate ^[94]^B2b. Safety: NRG-BR001 no dose-limiting toxicities ^[88]^C4; LUSTRE trial 3-year local control 87.6% with caution for ultra-central tumors ^[80]^A1b. Meta-analysis of ultra-central SBRT: 2-year local control 84%, grade ≥3 toxicity 9% ^[92]^B2a. Quality of life stable with SBRT ^[93]^B2b. Pearl: In treatment-naïve EGFR-mutant oligometastatic NSCLC (≤5 lesions), adding upfront SBRT to lazertinib yields a median PFS of 34 months with no grade ≥3 radiation pneumonitis ^[81]^B2b, a strategy that may obviate the need for combination chemotherapy or bispecific antibody therapy in selected patients.

Selected Trials of SBRT in Oligometastatic NSCLC

Study	Setting	Regimen	Key Efficacy Outcome	Safety
ABLATE (phase II) ^[81]^B2b	EGFR‑mutant, ≤5 lesions	Lazertinib 240 mg + SBRT vs lazertinib	Median PFS 34.0 vs 24.8 months	No grade ≥3 pneumonitis
SKYROCKET (phase II) ^[86]^B2b	PD‑L1+ advanced NSCLC	SBRT to all sites + atezolizumab + tiragolumab	Median PFS 9.3 months (95% CI 6.0‑NR)	No new safety signals
Bone SBRT cohort ^[94]^B2b	NSCLC, ≤5 bone metastases	SBRT to bone lesions	2‑yr FFLR 87.2%	5.4% fracture; no grade 4-5 AEs
NRG‑BR001 (phase I) ^[88]^C4	3-4 metastases or 2 in close proximity	SBRT per site‑specific schedule	No DLTs; median survival NR	No treatment‑related deaths

Prognosis of Recurrent Disease

▸Postoperative recurrence has better prognosis than de novo advanced disease
▸Time to recurrence >3 years is favorable

CP Clinical Pearl: Recurrence >3 years after surgery predicts better outcome and higher likelihood of multigene testing

Prognosis depends on disease extent, molecular drivers, and time to recurrence. Postoperative recurrence has better prognosis than de novo advanced disease (median survival 44.5 vs 27.5 months in EGFR-mutant patients on gefitinib) ^[98]^A1b. Visceral pleural invasion (VPI) upstages to pT2 and increases recurrence risk (5-year DFS 53.3% vs 65.9%) ^[108]^A1b. Inflamed immune phenotype (CD8+ T-cell rich) confers better outcome (HR 0.61) ^[96]^B2b. ALBI grade is independent prognostic factor on immunotherapy (grade 2 vs 1: HR 1.60) ^[23]^B3b. Time to recurrence >3 years after surgery is favorable ^[107]^B3b. Molecular drivers: EGFR mutation, MET amplification benefit from targeted therapy. KEAP1/STK11 co-mutations are poor prognostic ^[96]^B2b. After SABR for stage I-II, 5-year distant recurrence rate 19.9%, isolated locoregional recurrence in 34% of recurrences ^[24]^B3b. Multigene testing at recurrence is underutilized (43.7%) ^[107]^B3b.

Factor	Good Prognosis	Poor Prognosis
Disease extent at recurrence	Postoperative (median 44.5 mo) ^[98]^A1b	De novo stage IIIB/IV (median 27.5 mo) ^[98]^A1b
Visceral pleural invasion	No VPI: 5-year DFS 65.9% ^[108]^A1b	VPI: 5-year DFS 53.3% ^[108]^A1b
Immune phenotype	Inflamed: HR 0.61 ^[96]^B2b	Non-inflamed; KEAP1/STK11 co-mutations ^[96]^B2b
ALBI grade	Grade 1	Grade 2-3 ^[23]^B3b
Time to recurrence	>3 years ^[107]^B3b	≤3 years ^[107]^B3b
Performance status	ECOG 0-1	ECOG ≥2 ^[107]^B3b
Molecular drivers	EGFR mutation; MET+ ^[103]^B2b	Absence of targetable driver; STK11/KEAP1 ^[96]^B2b

Pearl: In patients with recurrent NSCLC, the best prognostic factor is the time to recurrence - postoperative recurrence carries a median survival approximately 17 months longer than de novo stage IIIB/IV disease in EGFR-mutant patients ^[98]^A1b. Visceral pleural invasion and a non-inflamed immune phenotype (especially with KEAP1/STK11 co-mutations) identify patients at highest risk and should prompt aggressive surveillance and consideration of adjuvant therapy ^[96]^B2b^[108]^A1b.

Key Prognostic Factors in Recurrent NSCLC

Factor	Good Prognosis	Poor Prognosis
Disease extent at recurrence	Postoperative recurrence (median survival 44.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b	De novo stage IIIB/IV disease (median survival 27.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b
Visceral pleural invasion (VPI)	pT1 tumors (no VPI): 5-year DFS 65.9%, recurrence rate 27.6% ^[108]^A1b	pT2 tumors (VPI): 5-year DFS 53.3%, recurrence rate 41.6% ^[108]^A1b
Immune phenotype	Inflamed phenotype (CD8+ T-cell rich): HR 0.61 for disease-specific survival, HR 0.65 for time to recurrence ^[96]^B2b	Non-inflamed (altered/desert) phenotype; KEAP1/STK11 co-mutations enriched in non-inflamed LUAD ^[96]^B2b
Albumin-bilirubin (ALBI) grade	ALBI grade 1: significantly longer PFS and OS on anti-PD-1 therapy ^[23]^B3b	ALBI grade 2-3: shorter PFS and OS; ALBI grade is an independent prognostic factor ^[23]^B3b
Time to recurrence	Recurrence >3 years after surgery (associated with higher multigene testing rate) ^[107]^B3b	Recurrence ≤3 years after surgery ^[107]^B3b
Performance status	ECOG PS 0-1	ECOG PS ≥2 (associated with older age, less biomarker testing) ^[107]^B3b
Molecular drivers	EGFR mutation (exon 19 deletion or L858R) - median OS ~35-37 months with first-line TKI ^[98]^A1b; MET-positive tumors benefit from MET inhibition ^[103]^B2b	Absence of targetable driver; STK11/KEAP1 mutations ^[96]^B2b

References

[1]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545176 ↗
L1GUIDELINECited in: Patterns of Recurrence, Workup of Suspected Recurrence
[2]
Yan TD, Black D, Bannon PG et al.. “Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19289625 ↗
L1SR_MA_RCTCited in: Patterns of Recurrence
[3]
Sugawara S, Lee JS, Kang JH et al.. “Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34139272 ↗
L1RCTCited in: Patterns of Recurrence
[4]
Tanvetyanon T, Robinson LA, Schell MJ et al.. “Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18309950 ↗
L2SR_COHORTCited in: Patterns of Recurrence
[5]
Brahmer JR, Lee JS, Ciuleanu TE et al.. “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36223558 ↗
L1RCTCited in: Patterns of Recurrence
[6]
Jänne PA, Planchard D, Kobayashi K et al.. “CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 38042525 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease
[7]
Zhang Y, Qian B, Song Q et al.. “Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40690727 ↗
L1RCTCited in: Patterns of Recurrence
[8]
Besse B, Mazières J, Ribassin-Majed L et al.. “Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28327934 ↗
L2RCT_PHASE2Cited in: Patterns of Recurrence, Prognosis of Recurrent Disease
[9]
Allignet B, De Ruysscher D, Martel-Lafay I et al.. “Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.” Cancer treatment reviews (2023). PMID: 37210766 ↗
L4SR_COHORTCited in: Patterns of Recurrence, Oligometastatic Disease
[10]
Wink KCJ, van Baardwijk A, Troost EGC et al.. “Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.” Cancer treatment reviews (2017). PMID: 28437679 ↗
L2SR_COHORTCited in: Patterns of Recurrence, Oligometastatic Disease
[11]
Peters S, Bexelius C, Munk V et al.. “The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.” Cancer treatment reviews (2016). PMID: 27019457 ↗
L2SR_COHORTCited in: Patterns of Recurrence
[12]
Yoshimura A, Takeda T, Tanimura K et al.. “Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study.” ESMO open (2025). PMID: 41270701 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[13]
Ito K, Morise M, Wakuda K et al.. “A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.” ESMO open (2021). PMID: 33984681 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[14]
Jamal-Hanjani M, Wilson GA, McGranahan N et al.. “Tracking the Evolution of Non-Small-Cell Lung Cancer.” The New England journal of medicine (2017). PMID: 28445112 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[15]
Yue D, Huang M, Song P et al.. “Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicine (2026). PMID: 42418775 ↗
L1RCTCited in: Patterns of Recurrence
[16]
Borghaei H, O'Byrne KJ, Paz-Ares L et al.. “Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.” ESMO open (2023). PMID: 37988950 ↗
L1RCTCited in: Patterns of Recurrence
[17]
O'Byrne KJ, Lee KH, Kim SW et al.. “First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.” ESMO open (2022). PMID: 35158207 ↗
L1RCTCited in: Patterns of Recurrence
[18]
Reck M, Ciuleanu TE, Cobo M et al.. “First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.” ESMO open (2021). PMID: 34607285 ↗
L1RCTCited in: Patterns of Recurrence
[19]
Paz-Ares L, Ciuleanu TE, Cobo M et al.. “First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33476593 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
[20]
Péchoux CL, Sun A, Slotman BJ et al.. “Prophylactic cranial irradiation for patients with lung cancer.” The Lancet. Oncology (2016). PMID: 27396646 ↗
L1RCTCited in: Patterns of Recurrence
[21]
Chun SG, Hu C, Choy H et al.. “Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28034064 ↗
L1RCTCited in: Workup of Suspected Recurrence, Prognosis of Recurrent Disease
[22]
Madan R, El Alam RH, Walker CM et al.. “ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy.” Journal of the American College of Radiology : JACR (2025). PMID: 40409885 ↗
L1GUIDELINECited in: Workup of Suspected Recurrence
[23]
Takada K, Takamori S, Shimokawa M et al.. “Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy.” ESMO open (2021). PMID: 34942439 ↗
L3COHORTCited in: Workup of Suspected Recurrence, Prognosis of Recurrent Disease
[24]
Senthi S, Lagerwaard FJ, Haasbeek CJ et al.. “Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.” The Lancet. Oncology (2012). PMID: 22727222 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence, Local-Regional Recurrence, Prognosis of Recurrent Disease
[25]
Loganadane G, Martinetti F, Mercier O et al.. “Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.” Cancer treatment reviews (2016). PMID: 27768919 ↗
L5NARRATIVE_REVIEWCited in: Workup of Suspected Recurrence
[26]
Xia L, Mei J, Kang R et al.. “Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34844976 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[27]
Sandhu SK, Schelman WR, Wilding G et al.. “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.” The Lancet. Oncology (2013). PMID: 23810788 ↗
L4PHASE_1_TRIALCited in: Workup of Suspected Recurrence
[28]
Guldbrandsen KF, Bloch M, Skougaard K et al.. “Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial.” Clinical lung cancer (2025). PMID: 41387040 ↗
L1RCTCited in: Workup of Suspected Recurrence
[29]
Zhang JT, Liu SY, Gao X et al.. “Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39853318 ↗
L4COHORTCited in: Workup of Suspected Recurrence
[30]
Arcidiacono F, Anselmo P, Casale M et al.. “Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40992670 ↗
L2RCT_PHASE2Cited in: Workup of Suspected Recurrence
[31]
Wu J, Zhang Y, Wang J et al.. “Accuracy of Radiomics-Based Machine Learning for Predicting Risk of Recurrence in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 41940422 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[32]
Yang Y, He H, Yu C et al.. “Artificial Intelligence Models to Predict Recurrence Risk Prediction in Early-Stage Non-Small Cell Lung Cancer: A Systematic Review.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 41666303 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[33]
Lu D, Lin N, Li S et al.. “Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis.” JCO precision oncology (2025). PMID: 41066727 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[34]
Lanuti M, Suh RD, Criner GJ et al.. “Systematic Review of Image-Guided Thermal Ablation for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2024). PMID: 39662536 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[35]
Hou J, Xiao J, Yang B et al.. “Value of RASSF1A and SHOX2 methylation detection in intraoperative pleural lavage fluid for potential microdissemination and prognosis evaluation in non-small cell lung cancer.” World journal of surgical oncology (2026). PMID: 42116130 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[36]
Toth AJ, Robert SM, Fahy T et al.. “Multidisciplinary review outperforms qualitative MR perfusion in distinguishing post-radiation brain metastasis recurrence versus radionecrosis.” Journal of neuro-oncology (2025). PMID: 41219616 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[37]
Xia L, Pu Q, Kang R et al.. “Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).” Journal of the National Cancer Institute (2025). PMID: 40131728 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[38]
. “MRD May Predict Relapse in NSCLC.” Cancer discovery (2020). PMID: 32467342 ↗
L5OTHERCited in: Workup of Suspected Recurrence
[39]
Chen K, Yang F, Shen H et al.. “Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.” Cancer cell (2023). PMID: 37683638 ↗
L5OTHERCited in: Workup of Suspected Recurrence
[40]
Simone CB, Amini A, Chetty IJ et al.. “American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary.” International journal of radiation oncology, biology, physics (2025). PMID: 40185207 ↗
L1GUIDELINECited in: Local-Regional Recurrence
[41]
Ciammella P, Iori F, Borghetti P et al.. “Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).” Lung cancer (Amsterdam, Netherlands) (2025). PMID: 40876065 ↗
L2PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[42]
Munoz-Schuffenegger P, Kandel S, Alibhai Z et al.. “A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2019). PMID: 31176537 ↗
L4PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[43]
Brooks ED, Sun B, Feng L et al.. “Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.” JAMA network open (2018). PMID: 30646121 ↗
L2PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[44]
Tane S, Nishikubo M, Manabe T et al.. “Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study.” Annals of surgical oncology (2026). PMID: 41746575 ↗
L4COHORTCited in: Local-Regional Recurrence
[45]
Vuppala NK, LeCompte MC, Patel PP et al.. “Oncological outcomes and safety after spinal reirradiation with stereotactic body radiotherapy.” Journal of neurosurgery. Spine (2025). PMID: 40939207 ↗
L3COHORTCited in: Local-Regional Recurrence
[46]
Odwuor A, Lee P, Chang JY et al.. “Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.” Clinical lung cancer (2025). PMID: 40318943 ↗
L4COHORTCited in: Local-Regional Recurrence
[47]
Lococo F, Cancellieri A, Chiappetta M et al.. “Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.” Clinical lung cancer (2023). PMID: 37061413 ↗
L4COHORTCited in: Local-Regional Recurrence
[48]
Zhang J, Mao J, Xu D et al.. “Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.” Cancer medicine (2022). PMID: 36524618 ↗
L3COHORTCited in: Local-Regional Recurrence
[49]
Joosten PJM, Dickhoff C, van der Noort V et al.. “Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?” Lung cancer (Amsterdam, Netherlands) (2020). PMID: 33220611 ↗
L3COHORTCited in: Local-Regional Recurrence
[50]
Muller DA, Dutta SW, Aliotta E et al.. “Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.” Clinical lung cancer (2020). PMID: 32690439 ↗
L4COHORTCited in: Local-Regional Recurrence
[51]
Kowalchuk RO, Waters MR, Richardson KM et al.. “Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer.” Practical radiation oncology (2020). PMID: 32454175 ↗
L4COHORTCited in: Local-Regional Recurrence
[52]
Kobayashi AK, Horinouchi H, Nakayama Y et al.. “Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients.” Lung cancer (Amsterdam, Netherlands) (2020). PMID: 32422344 ↗
L4COHORTCited in: Local-Regional Recurrence
[53]
Saleh K, Daste A, Martin N et al.. “Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.” European journal of cancer (Oxford, England : 1990) (2019). PMID: 31574417 ↗
L4COHORTCited in: Local-Regional Recurrence
[54]
Grass GD, Naghavi AO, Abuodeh YA et al.. “Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients.” Clinical lung cancer (2018). PMID: 30268836 ↗
L3COHORTCited in: Local-Regional Recurrence
[55]
Chao HH, Berman AT, Simone CB et al.. “Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2016). PMID: 27826034 ↗
L4COHORTCited in: Local-Regional Recurrence
[56]
Dickhoff C, Dahele M, Paul MA et al.. “Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2016). PMID: 26973215 ↗
L4COHORTCited in: Local-Regional Recurrence
[57]
Binkley MS, Hiniker SM, Chaudhuri A et al.. “Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.” International journal of radiation oncology, biology, physics (2015). PMID: 26831903 ↗
L4COHORTCited in: Local-Regional Recurrence
[58]
Mizobuchi T, Yamamoto N, Nakajima M et al.. “Salvage surgery for local recurrence after carbon ion radiotherapy for patients with lung cancer.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015). PMID: 26468271 ↗
L3COHORTCited in: Local-Regional Recurrence
[59]
Liao Z, Lee JJ, Komaki R et al.. “Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29293386 ↗
L1RCTCited in: Distant Metastatic Disease
[60]
Scagliotti GV, Krzakowski M, Szczesna A et al.. “Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22564989 ↗
L1RCTCited in: Distant Metastatic Disease
[61]
Kurup A, Lin C-, Murry DJ et al.. “Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16282244 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[62]
Yang JT, Wijetunga NA, Pentsova E et al.. “Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35802849 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[63]
Yang JC, Wang M, Doucet L et al.. “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40923280 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[64]
Le X, Patel JD, Shum E et al.. “A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39378386 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[65]
Li Z, Hu J, Chen J et al.. “Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42296979 ↗
L1RCTCited in: Distant Metastatic Disease
[66]
Antonia SJ, Villegas A, Daniel D et al.. “Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.” The New England journal of medicine (2018). PMID: 30280658 ↗
L1RCTCited in: Distant Metastatic Disease
[67]
Goldberg SB, Schalper KA, Gettinger SN et al.. “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2020). PMID: 32251621 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[68]
Goldberg SB, Gettinger SN, Mahajan A et al.. “Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2016). PMID: 27267608 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[69]
Hui Z, Men Y, Hu C et al.. “Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34165501 ↗
L1RCTCited in: Distant Metastatic Disease
[70]
Wang HM, Liao ZX, Komaki R et al.. “Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23300016 ↗
L2PROSPECTIVE_COHORTCited in: Distant Metastatic Disease
[71]
Akamatsu H, Toi Y, Hayashi H et al.. “Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33410885 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[72]
Provencio M, Serna-Blasco R, Nadal E et al.. “Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41537692 ↗
L1RCTCited in: Distant Metastatic Disease
[73]
Santini D, Galluzzo S, Vincenzi B et al.. “New developments of aminobisphosphonates: the double face of Janus.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591815 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[74]
Park S, Lee MH, Seong M et al.. “A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32634610 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[75]
Le X, Cornelissen R, Garassino M et al.. “Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34843401 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[76]
Welsh JW, Komaki R, Amini A et al.. “Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23341526 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[77]
Chen L, Davelaar J, Gaddam S et al.. “Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36395704 ↗
L4CASE_SERIESCited in: Distant Metastatic Disease
[78]
Altorki NK, McGraw TE, Borczuk AC et al.. “Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.” The Lancet. Oncology (2021). PMID: 34015311 ↗
L2RCT_PHASE2Cited in: Oligometastatic Disease
[79]
Baumann P, Nyman J, Hoyer M et al.. “Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19414667 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[80]
Swaminath A, Parpia S, Wierzbicki M et al.. “Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 39298144 ↗
L1RCTCited in: Oligometastatic Disease
[81]
Lee JB, Kim KH, Yoon S et al.. “Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.” ESMO open (2026). PMID: 41604814 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[82]
Heinzerling JH, Mileham KF, Robinson MM et al.. “Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 39615497 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[83]
Theelen WSME, Peulen HMU, Lalezari F et al.. “Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.” JAMA oncology (2019). PMID: 31294749 ↗
L2RCT_PHASE2Cited in: Oligometastatic Disease
[84]
Bezjak A, Paulus R, Gaspar LE et al.. “Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30943123 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[85]
Simpson DR, Sanghvi P, Sandhu AP. “Lung stereotactic body radiotherapy for early-stage NSCLC in patients with prior pneumonectomy: a case report.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25361797 ↗
L4CASE_SERIESCited in: Oligometastatic Disease
[86]
Lee JB, Kim DK, Lee SH et al.. “A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 42008740 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[87]
Wang Y, Donovan EK, Levine MN et al.. “Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial.” Clinical lung cancer (2026). PMID: 41997828 ↗
L1RCTCited in: Oligometastatic Disease
[88]
Chmura S, Winter KA, Robinson C et al.. “Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.” JAMA oncology (2021). PMID: 33885704 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[89]
Asami M, Katsumata S, Yasui K et al.. “Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer.” Japanese journal of clinical oncology (2026). PMID: 41215492 ↗
L1RCTCited in: Oligometastatic Disease
[90]
Zhou X, Zhou L, Yao Z et al.. “Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37581611 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[91]
Adar S, Ádám A, Balogh T et al.. “Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42202379 ↗
L2SR_COHORTCited in: Oligometastatic Disease
[92]
Zeng H, Wang X, Bai H et al.. “Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.” Radiation oncology (London, England) (2026). PMID: 42116164 ↗
L2SR_COHORTCited in: Oligometastatic Disease
[93]
Greto D, Van Hemelrijck M, Oppong F et al.. “Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42314835 ↗
L2PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[94]
Schäfer S, Seiler I, Balermpas P et al.. “Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.” Radiation oncology (London, England) (2026). PMID: 42157246 ↗
L2PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[95]
Zygogianni A, Kougioumtzopoulou A, Platoni K et al.. “Real-World Data on the Safety and Efficacy of SBRT for Central and Ultra-Central Lung Tumors: A Retrospective Multi-Center Cohort.” Cancers (2026). PMID: 41749905 ↗
L4PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[96]
Rakaee M, Andersen S, Giannikou K et al.. “Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37100205 ↗
L2PROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[97]
Kelly RJ, Shepherd FA, Krivoshik A et al.. “A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31070709 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[98]
Yoshioka H, Shimokawa M, Seto T et al.. “Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31553438 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[99]
Reck M, von Pawel J, Zatloukal P et al.. “Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20150572 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[100]
Landreneau RJ, Normolle DP, Christie NA et al.. “Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24982447 ↗
L2PROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[101]
Zhou C, Wu YL, Chen G et al.. “BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26014294 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[102]
Vansteenkiste JF, Cho BC, Vanakesa T et al.. “Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2016). PMID: 27132212 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[103]
Spigel DR, Ervin TJ, Ramlau RA et al.. “Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24101053 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[104]
Kubota K, Yoshioka H, Oshita F et al.. “Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28902534 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[105]
Schild SE, Vokes EE. “Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712904 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis of Recurrent Disease
[106]
Siena S, Crinò L, Danova M et al.. “Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19767314 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis of Recurrent Disease
[107]
Matsubara T, Sakamoto T, Takahama T et al.. “Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.” ESMO open (2026). PMID: 41922144 ↗
L3RETROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[108]
Altorki N, Wang X, Damman B et al.. “Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2024). PMID: 39088196 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[109]
Chang JY, Senan S, Paul MA et al.. “Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.” The Lancet. Oncology (2015). PMID: 25981812 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[110]
Kim ES, Neubauer M, Cohn A et al.. “Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.” The Lancet. Oncology (2013). PMID: 24231627 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease